

# IN THE U<u>NITED STATES PATENT AND TRADEMARK OFFICE</u>

Sosnowski et al. Examiner: Unassigned

> (Parent Application Examiner: S.A. Jiang)

Serial No.: 10/601,942 Group Art Unit: Unassigned

> (Parent Application Group Art Unit: 1617)

October 6, 2003

Filed: June 23, 2003 Docket No.: 1107-3 CON

Confirmation No.: 7841 Customer No.: 33769

For: Composition And Method Dated:

For Reducing The Risk Or

Progression Of

Cardiovascular, Glaucoma And Tardive Dyskinesia

**Diseases** 

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail,

postpaid in an envelope, addressed to: Commissioner for Patents, P.O. Box 1450.

Alexandria, Virginia 22313-1450

P.O. Box 1450

Alexandria, VA 22313-1450

Commissioner for Patents

### INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

### **UNITED STATES PATENTS**

<u>PATENTEE</u>	PATENT NO.	ISSUE DATE
Fogel	5,866,585	Feb. 2, 1999
Wakat	6,054,128	Apr. 25, 2000
Lipton et al.	5,922,773	Jul. 13, 1999
Rosenquist et al.	6,025,369	Feb. 15, 2000

### **FOREIGN DOCUMENTS**

Henderson, Janeel WO 00/37087 A1 June 29, 2000

### **NON-PATENT PUBLICATION**

Bucci, L.R., FDA filing reference, August 27, 1999, pp.1 and 2.

Pei I. Ho et al., Multiple Aspects of Homocysteine Neurotoxicity: Glutamate Excitotoxicity, Kinase Hyperactivation and DNA Damage, Journal of Neuroscience Research 70:694-702 (December, 2002).

Seshadri, S. et al., Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease, 1: N Engl J Med. 2002 Feb 14; 346(7):476-83.

Fonseca, V.A. et al., Insulin Sensitivity and Plasma Homocysteine Concentrations in Non-Diabetic Obese and Normal Weight Subjects, Atherosclerosis, 2003 March; 167(1):105-9.

A. Ambrosch et al., Relation Between Homocysteinaemia and Diabetic Neuropathy in Patients with Type 2 Diabetes, Diabetic Medicine, Volume 18, Issue 3, p.185, March 2001.

Pamela Moore et al., Apoptotic Cell Death in the Mouse Retinal Ganglion Cell Layer is Induced in Vivo by the Excitatory Amino Acid Homocysteine, Exp Eye Res. 73(1), pp. 45-57, July, 2001, Academic Press.

Centrum references, Whitehall Robins: Centrum Focused Formulas Heart and Centrum Herbals Ginkgo, from www.centrum.com.

McCully, Kilmer S., M.D., *The Homocysteine Revolution "A Bold New Approach to the Prevention of Heart Disease"*, Keats Publishing, Los Angeles 1997, pp. 33, 64-65, 92-105, 137, 181.

Bleich S., Degner, D., Bandelow, B., von Ahsen, N., Ruther, E., Kornhuber, J., Plasma Homocysteine is a Predictor of Alcohol Withdrawal Seizures, Neuroreport 2000, Aug. 21

Abstract.

The above-referenced documents are listed on PTO Form 1449. We have enclosed

the cited documents to facilitate reference to them.

Applicants are not aware of any other references to be identified at this time. If the

Examiner has any questions or comments relating to the present application, he or she is

respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,

Gerald T. Bodner

Registration No. 30,449

Attorney for Applicants

Gerald T. Bodner, Esq. BODNER & O'ROURKE, LLP 425 Broadhollow Road

Suite 108

Melville, NY 11747

Telephone: (631) 249-7500 Facsimile: (631) 249-4508

GTB/bi

3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

OIPE CON B 2003 EN THADENERS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1107-3 CON	10/601,942
APPLICANT	CUSTOMER NO.
Sosnowski, et al.	33769
FILING DATE	GROUP ART UNIT
June 23, 2003	Unassigned

#### U.S. PATENT DOCUMENTS

			.5. FAILT	AT DOCUMENTS	•			
EXAMINER INITIAL	DOCUMENT NUMBER	D/	ATE	NAME	CLASS	SUB CLASS		DATE OPRIATE
	5,866,585	2/2/	99 Fog	gel				
	6,054,128	4/25	7/00 Wa	kat				
	5,922,773	7/13	/99 Lip	ton et al.				
	6,025,369	2/15	i/00 Ros	senquist et al.				
		<u> </u>						
		FOR	EIGN PAT	TENT DOCUMEN	NTS			
EXAMINER		DOCUMENT		TE COUNTRY	CLASS	SUB	TRANSLATION	
INITIAL	NUMBER	-			32.55	CLASS	YES	NO

# WO 00/37087 A1 6/29/00 PCT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Bucci, L.R., FDA filing reference, August 27, 1999, pp. 1 and 2.

Pei I. Ho et al., Multiple Aspects of Homocysteine Neurotoxicity:
Glutamate Excitotoxicity, Kinase Hyperactivation and DNA Damage,
Journal of Neuroscience Research 70:694-702 (December, 2002).

### **EXAMINER**

### DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-16 (Rev. 2-32)	149 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1107-3 CON	SERIAL NO. 10/601,942	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Sosnowski, et al.	CUSTOMER NO. 33769	
1 0 8 20C3 E	(Use several sheets if necessary)	FILING DATE June 23, 2003	GROUP ART UNIT Unassigned	
& TRADERACH	Seshadri, S. et al., Plasma He and Alzheimer's Disease, 1:			
	Fonseca, V.A. et al., Insulin a Concentrations in Non-Diab Atherosclerosis, 2003 March	etic Obese and Normal		
	A. Ambrosch et al., Relation Neuropathy in Patients with 18, Issue 3, p.185, March 200	Type 2 Diabetes, Diabet		
	Pamela Moore et al., Apopto Cell Layer is Induced in Vivo Exp Eye Res. 73(1), pp. 45-5	by the Excitatory Amin	o Acid Homocysteine	
	Centrum references, Whiteha Heart and Centrum Herbals			
	McCully, Kilmer S., M.D., T Approach to the Prevention of Angeles 1997, pp. 33, 64-65,	of Heart Disease", Keat		
	Bleich S., Degner, D., Bande Kornhuber, J., Plasma Homo Withdrawal Seizures, Neuron	cysteine is a Predictor o	of Alcohol	

# **EXAMINER**

## **DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.